Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for RAPT Therapeutics in a note issued to investors ...

RAPT Therapeutics (NASDAQ:RAPT – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

General and administrative expenses for the fourth quarter of 2024 were $8.0 million, compared to $6.5 million for the same period in 2023. The increase in general and administrative expenses was ...

Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and underserved ...

RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused ...

BizTrendsTV takes Bizcommunity’s annual award-winning trend reports to an exciting new level, curating insights from Africa’s ...

RAPT THERAPEUTICS ($RAPT) posted quarterly earnings results on Thursday, March 6th. The company reported earnings of -$1.14 per share, missing estimates of -$0.38 by ...

RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology ...

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing ...